A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Enovis Corporation (the “Company”, “Enovis”, “we” or “us”) is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing, and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. Our products address the continuum of patient care from injury prevention to rehabilitation after surgery or injury or from degenerative disease, enabling people to regain or maintain their natural motion. We seek to leverage our Enovis Growth Excellence business system (“EGX”), a set of tools, processes, and culture, to continuously improve our ability to enable great patient outcomes and to drive and fuel growth. During the year ended December 31, 2025, we completed four acquisitions within our Reconstructive segment and three acquisitions within our Prevention & Recovery segment.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 2.2B | 2.2B | 2.1B | 1.7B | 1.6B | 1.4B |
| Net Income | -1.2B | -1.2B | -825M | -33M | -13M | 72M |
| EPS | $-20.75 | $-20.75 | $-14.93 | $-0.61 | $-0.25 | $1.40 |
| Free Cash Flow | 20M | 20M | -67M | 13M | -161M | 252M |
| ROIC | -31.9% | -35.8% | -21.3% | -0.9% | -0.4% | 1.1% |
| Gross Margin | 59.8% | 59.8% | 56.0% | 58.0% | 55.6% | 54.5% |
| Debt/Equity | 0.89 | 0.89 | 0.53 | 0.14 | 0.14 | 0.45 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -1.1B | -1.1B | -776M | -66M | -71M | -63M |
| Operating Margin | -50.0% | -50.0% | -36.8% | -3.8% | -4.6% | -4.4% |
| ROE | -79.5% | -58.5% | -32.2% | -1.0% | -0.4% | 1.6% |
| Shares Outstanding | 57M | 57M | 55M | 55M | 53M | 51M |
Enovis CORP passes 1 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 71.2x vs a median of 25.6x. The company's 5-year average gross margin is 56.8%. Total shareholder yield (buybacks) is 0.2%. At current prices, the estimated annualized return to fair value is -32.4%.
Enovis CORP (ENOV) has a 5-year average return on invested capital (ROIC) of -11.5%. This is below average and may indicate limited pricing power.
Enovis CORP (ENOV) has a market capitalization of $1.4B. It is classified as a small-cap stock.
Enovis CORP (ENOV) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.25%.
Enovis CORP (ENOV) operates in the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry, within the Healthcare sector.
Enovis CORP (ENOV) reported annual revenue of $2.2 billion in its most recent fiscal year, based on SEC EDGAR filings.
Enovis CORP (ENOV) has a net profit margin of -52.7%. The company is currently unprofitable.
Enovis CORP (ENOV) generated $20 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Enovis CORP (ENOV) has a debt-to-equity ratio of 0.89. This indicates moderate leverage.
Enovis CORP (ENOV) reported earnings per share (EPS) of $-20.75 in its most recent fiscal year.
Enovis CORP (ENOV) has a return on equity (ROE) of -58.5%. A negative ROE may indicate losses or negative equity.
Enovis CORP (ENOV) has a 5-year average gross margin of 56.8%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for Enovis CORP (ENOV), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Enovis CORP (ENOV) has a book value per share of $26.10, based on its most recent annual SEC filing.
No recent press releases.